Vixa Skineal .25 mg/g; 10 mg/g; 5000 [iU]/g Cream, 15 g — NDC 84659-9040-1 (Billing 84659-9040-01)
This is a package of 15 g of Vixa Skineal .25 mg/g; 10 mg/g; 5000 [iU]/g Cream from Yunnan Yuyao Bio-pharmaceutical Co.,Ltd., no longer marketed (first marketed Jun 2024), no longer in the FDA NDC Directory. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 84659-9040-1 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 84659 labeler · 9040 product · 1 package
- Package marketed since
- Jun 1, 2024
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 8465990401 9
- FDA record last changed
- Jul 30, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 20, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Vixa Skineal is a topical cream containing three active ingredients: clobetasol propionate (a potent corticosteroid), ketoconazole (an antifungal agent), and neomycin sulfate (an antibiotic). These ingredients are typically combined in products intended to address skin conditions involving inflammation, fungal infection, and bacterial infection. This product is marketed without an approved FDA application.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 20, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 84659-9040-01 You're viewing this Main listing | 15 g in 1 BOX | 2024-06-01 | — | Inactivated by FDA |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Vixa Skineal .25 mg/g; 10 mg/g; 5000 [iU]/gthis 84659-9040-01 | Yunnan | 15 g | — | — | Discontinued | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Nov 20, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION: Apply externally to affected area twice daily. It is suggested to use for 2 weeks on ordinary tinea corporis and tinea cruris, for 4 weeks on tinea pedis and tinea manus. SIDE EFFECTS: VIXA SKINEAL has few side effects when used topically. A few instance of irritation or burning sensation may be observed occasionally during the treatment. But usually, it is unnecessary to stop the drug. CONTRAINDICATION:
📄 Package Label / Principal Display Panel ▾
DESCRIPTION: A white or off-white cream with emulsive base. PHARMACOLOGICAL ACTIONS: Ketoconazole is a broad-spectrum anti-fungal agent that acts on the cell membranes of fungi by changing its permeability. Pharmacological studies have shown that Ketoconazole has extremely potent antimycotic actions against dermatophytes (such as Trichophyton sp., Microsporum sp., and epidermophyton sp.), saccharomyces and candida albicans.
Strains of fungi are unlikely to have a natural resistance to Ketoconazole. Clobetasol Propionate is cortex hormone that is highly effective as an anti-inflammatory and anti-allergic agent with a few side effects. Neomycin Sulfate is effective against Gram-positive cocci and Gram-negative bacilli.
As a result, this compound cream is jointly effective against fungus, bacteria, inflammation and pruritus. INDICATIONS: VIXA SKINEAL is indicated for topical application on the treatment of fungal infection of skin, such as tinea manus, tinea pedis, tinea corporis, tinea cruris and tinea versicolor. It is also proved effective on the treatment of many kinds of dermatitis, eczema and pruritus.
DOSAGE AND ADMINISTRATION: Apply externally to affected area twice daily. It is suggested to use for 2 weeks on ordinary tinea corporis and tinea cruris, for 4 weeks on tinea pedis and tinea manus. SIDE EFFECTS: VIXA SKINEAL has few side effects when used topically.
A few instance of irritation or burning sensation may be observed occasionally during the treatment. But usually, it is unnecessary to stop the drug. CONTRAINDICATION: VIXA SKINEAL is contraindicated in patients with known hypersensitivity to any of its ingredients.
It is not for ophthalmic use. Take special precautions when using on pregnancy and infancy. PRECAUTIONS: It should be under doctor's supervision to apply VIXA SKINEAL on the face or on large areas for a long period of time.
PACKAGE: Each tube contains 15g. STORAGE: STORE IN A DRY PLACE BELOW 30°C AND AWAY FROM THE SUNLIGHT. EXPIRATION DATE: Three years after the manufacturing date.
FOR EXTERNAL USE ONLY. KEEP OUT OF REACH OF CHILDREN. AVOID CONTACTING EYES.
READ PACKAGE INSERT CAREFULLY BEFORE USING. BATCH NO., MFG. DATE, EXP.
DATE ON BOX CAP. Mfg. by: Yunnan Yuyao Bio-Pharmaceutical Co., Ltd. Address: High & New Technology Industries Development Zone, Yuxi City, Yunnan Province, P.R.China.
Labeling
About this NDC listing & data coverage
Listed without an FDA application
This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |